vs

Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and VSE CORP (VSEC). Click either name above to swap in a different company.

VSE CORP is the larger business by last-quarter revenue ($301.2M vs $164.7M, roughly 1.8× PTC THERAPEUTICS, INC.). VSE CORP runs the higher net margin — 4.5% vs -82.0%, a 86.5% gap on every dollar of revenue. On growth, VSE CORP posted the faster year-over-year revenue change (0.7% vs -22.7%). VSE CORP produced more free cash flow last quarter ($30.9M vs $-36.6M). Over the past eight quarters, VSE CORP's revenue compounded faster (11.7% CAGR vs -11.5%).

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

VSE Corporation is a leading provider of aftermarket distribution and repair services. Operating through its two key segments, VSE significantly enhances the productivity and longevity of its customers' high-value, business-critical assets. The aviation segment is a leading provider of aftermarket parts distribution and maintenance, repair, and overhaul (MRO) services for components and engine accessories to commercial, business, and general aviation operators. The fleet segment specializes i...

PTCT vs VSEC — Head-to-Head

Bigger by revenue
VSEC
VSEC
1.8× larger
VSEC
$301.2M
$164.7M
PTCT
Growing faster (revenue YoY)
VSEC
VSEC
+23.5% gap
VSEC
0.7%
-22.7%
PTCT
Higher net margin
VSEC
VSEC
86.5% more per $
VSEC
4.5%
-82.0%
PTCT
More free cash flow
VSEC
VSEC
$67.5M more FCF
VSEC
$30.9M
$-36.6M
PTCT
Faster 2-yr revenue CAGR
VSEC
VSEC
Annualised
VSEC
11.7%
-11.5%
PTCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PTCT
PTCT
VSEC
VSEC
Revenue
$164.7M
$301.2M
Net Profit
$-135.0M
$13.6M
Gross Margin
Operating Margin
-43.3%
10.8%
Net Margin
-82.0%
4.5%
Revenue YoY
-22.7%
0.7%
Net Profit YoY
-104.8%
3.9%
EPS (diluted)
$-1.63
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PTCT
PTCT
VSEC
VSEC
Q4 25
$164.7M
$301.2M
Q3 25
$211.0M
$282.9M
Q2 25
$178.9M
$272.1M
Q1 25
$1.2B
$256.0M
Q4 24
$213.2M
$299.0M
Q3 24
$196.8M
$273.6M
Q2 24
$186.7M
$266.0M
Q1 24
$210.1M
$241.5M
Net Profit
PTCT
PTCT
VSEC
VSEC
Q4 25
$-135.0M
$13.6M
Q3 25
$15.9M
$3.9M
Q2 25
$-64.8M
$3.2M
Q1 25
$866.6M
$-9.0M
Q4 24
$-65.9M
$13.1M
Q3 24
$-106.7M
$11.7M
Q2 24
$-99.2M
$-2.8M
Q1 24
$-91.6M
$-6.6M
Operating Margin
PTCT
PTCT
VSEC
VSEC
Q4 25
-43.3%
10.8%
Q3 25
1.4%
3.6%
Q2 25
-19.5%
8.3%
Q1 25
82.5%
9.6%
Q4 24
-76.2%
9.2%
Q3 24
-27.7%
8.7%
Q2 24
-21.5%
2.3%
Q1 24
-21.6%
10.0%
Net Margin
PTCT
PTCT
VSEC
VSEC
Q4 25
-82.0%
4.5%
Q3 25
7.5%
1.4%
Q2 25
-36.3%
1.2%
Q1 25
73.7%
-3.5%
Q4 24
-30.9%
4.4%
Q3 24
-54.2%
4.3%
Q2 24
-53.1%
-1.0%
Q1 24
-43.6%
-2.7%
EPS (diluted)
PTCT
PTCT
VSEC
VSEC
Q4 25
$-1.63
$0.64
Q3 25
$0.20
$0.19
Q2 25
$-0.83
$0.16
Q1 25
$10.04
$-0.44
Q4 24
$-0.85
$0.79
Q3 24
$-1.39
$0.63
Q2 24
$-1.29
$-0.16
Q1 24
$-1.20
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PTCT
PTCT
VSEC
VSEC
Cash + ST InvestmentsLiquidity on hand
$1.9B
$69.4M
Total DebtLower is stronger
$292.8M
Stockholders' EquityBook value
$-205.3M
$1.4B
Total Assets
$2.9B
$2.0B
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PTCT
PTCT
VSEC
VSEC
Q4 25
$1.9B
$69.4M
Q3 25
$1.7B
$8.8M
Q2 25
$2.0B
$16.9M
Q1 25
$2.0B
$5.7M
Q4 24
$1.1B
$29.0M
Q3 24
$1.0B
$7.9M
Q2 24
$1.1B
$19.0M
Q1 24
$884.8M
$10.6M
Total Debt
PTCT
PTCT
VSEC
VSEC
Q4 25
$292.8M
Q3 25
$356.1M
Q2 25
$379.2M
Q1 25
$465.0M
Q4 24
$430.2M
Q3 24
$450.3M
Q2 24
$463.5M
Q1 24
$481.6M
Stockholders' Equity
PTCT
PTCT
VSEC
VSEC
Q4 25
$-205.3M
$1.4B
Q3 25
$-155.8M
$983.3M
Q2 25
$-206.5M
$979.5M
Q1 25
$-185.8M
$975.7M
Q4 24
$-1.1B
$988.2M
Q3 24
$-1.1B
$787.8M
Q2 24
$-980.2M
$781.3M
Q1 24
$-893.9M
$612.7M
Total Assets
PTCT
PTCT
VSEC
VSEC
Q4 25
$2.9B
$2.0B
Q3 25
$2.6B
$1.6B
Q2 25
$2.6B
$1.6B
Q1 25
$2.7B
$1.7B
Q4 24
$1.7B
$1.7B
Q3 24
$1.8B
$1.5B
Q2 24
$1.9B
$1.5B
Q1 24
$1.8B
$1.3B
Debt / Equity
PTCT
PTCT
VSEC
VSEC
Q4 25
0.20×
Q3 25
0.36×
Q2 25
0.39×
Q1 25
0.48×
Q4 24
0.44×
Q3 24
0.57×
Q2 24
0.59×
Q1 24
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PTCT
PTCT
VSEC
VSEC
Operating Cash FlowLast quarter
$-34.3M
$37.6M
Free Cash FlowOCF − Capex
$-36.6M
$30.9M
FCF MarginFCF / Revenue
-22.3%
10.3%
Capex IntensityCapex / Revenue
1.4%
2.2%
Cash ConversionOCF / Net Profit
2.77×
TTM Free Cash FlowTrailing 4 quarters
$702.3M
$5.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PTCT
PTCT
VSEC
VSEC
Q4 25
$-34.3M
$37.6M
Q3 25
$-66.3M
$24.1M
Q2 25
$-58.3M
$11.9M
Q1 25
$870.1M
$-46.6M
Q4 24
$-30.0M
$55.4M
Q3 24
$-77.0M
$10.2M
Q2 24
$-71.5M
$-17.5M
Q1 24
$70.8M
$-79.1M
Free Cash Flow
PTCT
PTCT
VSEC
VSEC
Q4 25
$-36.6M
$30.9M
Q3 25
$-69.7M
$18.0M
Q2 25
$-59.6M
$6.3M
Q1 25
$868.4M
$-49.5M
Q4 24
$-33.8M
$52.1M
Q3 24
$-77.5M
$4.4M
Q2 24
$-78.8M
$-21.5M
Q1 24
$61.2M
$-86.8M
FCF Margin
PTCT
PTCT
VSEC
VSEC
Q4 25
-22.3%
10.3%
Q3 25
-33.1%
6.4%
Q2 25
-33.3%
2.3%
Q1 25
73.8%
-19.3%
Q4 24
-15.8%
17.4%
Q3 24
-39.4%
1.6%
Q2 24
-42.2%
-8.1%
Q1 24
29.1%
-35.9%
Capex Intensity
PTCT
PTCT
VSEC
VSEC
Q4 25
1.4%
2.2%
Q3 25
1.6%
2.1%
Q2 25
0.7%
2.1%
Q1 25
0.1%
1.1%
Q4 24
1.8%
1.1%
Q3 24
0.3%
2.1%
Q2 24
4.0%
1.5%
Q1 24
4.6%
3.2%
Cash Conversion
PTCT
PTCT
VSEC
VSEC
Q4 25
2.77×
Q3 25
-4.17×
6.16×
Q2 25
3.72×
Q1 25
1.00×
Q4 24
4.24×
Q3 24
0.87×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons